Author
Listed:
- Rodrigo Postigo
(European Medicines Agency)
- Sabine Brosch
(European Medicines Agency)
- Jim Slattery
(European Medicines Agency)
- Anja Haren
(Medicines Evaluation Board)
- Jean-Michel Dogné
(Agence Fédérale des Médicaments et des Produits de Santé (Member of the Pharmacovigilance Risk Assessment Committee))
- Xavier Kurz
(European Medicines Agency)
- Gianmario Candore
(European Medicines Agency)
- Francois Domergue
(European Medicines Agency)
- Peter Arlett
(European Medicines Agency)
Abstract
The analysis of safety data from spontaneous reporting systems has a proven value for the detection and analysis of the risks of medicines following their placement on the market and use in medical practice. EudraVigilance is the pharmacovigilance database to manage the collection and analysis of suspected adverse reactions to medicines authorised in the European Economic Area. EudraVigilance first operated in December 2001, with access to the database being governed by the EudraVigilance access policy. We performed a literature search including data up to December 2016 to demonstrate how the data from EudraVigilance has been used in scientific publications. We describe the results, including by type of publication, research topics and drugs involved. In 50% of the publications, the data are used to describe safety issues, in 44% to analyse methodologies used in pharmacovigilance activities and in 6% to support clinical perspectives. We also outline a description of the use of the database by the European Union regulatory network. Driven by the full implementation of the 2010 pharmacovigilance legislation, EudraVigilance has undergone further enhancements together with a major revision of its access policy, taking into account the use of the new individual case safety report standard developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and the International Organization for Standardization. The aim of the broadened access is to facilitate more effective safety monitoring of authorised medicines, to make more data available for research and to provide better access to information on suspected adverse reactions for healthcare professionals and patients. In November 2017, the new full functionalities of EudraVigilance were launched, including the extensive web access to data on suspected adverse drug reactions and the possibilities for academic research institutions to request a more extensive dataset for the purposes of health research. The main objective of this article is to describe the new access to the database together with the opportunities that this new access can bring for research. It is intended to promote an appropriate use of the data to support the safe and effective use of medicines.
Suggested Citation
Rodrigo Postigo & Sabine Brosch & Jim Slattery & Anja Haren & Jean-Michel Dogné & Xavier Kurz & Gianmario Candore & Francois Domergue & Peter Arlett, 2018.
"EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection,"
Drug Safety, Springer, vol. 41(7), pages 665-675, July.
Handle:
RePEc:spr:drugsa:v:41:y:2018:i:7:d:10.1007_s40264-018-0647-1
DOI: 10.1007/s40264-018-0647-1
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Kacper Wróbel & Beata Zastawna & Anna Justyna Milewska & Michał Marczak & Remigiusz Kozłowski, 2023.
"Comparison between the American and the European Systems of Monitoring Adverse Effects of Dietary Supplements and Their Usefulness on the Polish Market,"
IJERPH, MDPI, vol. 20(2), pages 1-19, January.
- Kamila Sienkiewicz & Monika Burzyńska & Izabela Rydlewska-Liszkowska & Jacek Sienkiewicz & Ewelina Gaszyńska, 2021.
"The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process,"
IJERPH, MDPI, vol. 19(1), pages 1-16, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:7:d:10.1007_s40264-018-0647-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.